164 related articles for article (PubMed ID: 29635472)
1. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis.
Zelenitsky SA; Beahm NP; Iacovides H; Ariano RE; Zhanel G
J Antimicrob Chemother; 2018 Jul; 73(7):1888-1894. PubMed ID: 29635472
[TBL] [Abstract][Full Text] [Related]
2. Ceftriaxone and methicillin-susceptible
Telles JP; Leme RCP; Campos ML; Ito C; Bail L; Nogueira KDS; Tuon FF
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1039-1048. PubMed ID: 34225556
[No Abstract] [Full Text] [Related]
3. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
Housman ST; Sutherland CA; Nicolau DP
Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
[TBL] [Abstract][Full Text] [Related]
4. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus.
Gern BH; Greninger AL; Weissman SJ; Stapp JR; Tao Y; Qin X
Ann Clin Microbiol Antimicrob; 2018 Feb; 17(1):5. PubMed ID: 29463249
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus: is it a viable treatment option?
Heffernan AJ; Sime FB; Lim SMS; Adiraju S; Wallis SC; Lipman J; Grant GD; Roberts JA
Int J Antimicrob Agents; 2022 Mar; 59(3):106537. PubMed ID: 35093539
[TBL] [Abstract][Full Text] [Related]
6. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.
Jain JG; Housman ST; Nicolau DP
J Antimicrob Chemother; 2014 Sep; 69(9):2443-7. PubMed ID: 24827890
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible
Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP
Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602
[TBL] [Abstract][Full Text] [Related]
9. Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia.
Sakoulas G; Olson J; Yim J; Singh NB; Kumaraswamy M; Quach DT; Rybak MJ; Pogliano J; Nizet V
Antimicrob Agents Chemother; 2016 Nov; 60(11):6609-6618. PubMed ID: 27572414
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus.
Salvador E; Oualha M; Bille E; Beranger A; Moulin F; Benaboud S; Boujaafar S; Gana I; Urien S; Zheng Y; Toubiana J; Briand C; Bustarret O; Geslain G; Renolleau S; Treluyer JM; Hirt D
Clin Microbiol Infect; 2021 Mar; 27(3):413-419. PubMed ID: 32360445
[TBL] [Abstract][Full Text] [Related]
12. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF
J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
[TBL] [Abstract][Full Text] [Related]
15. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
[TBL] [Abstract][Full Text] [Related]
16. Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis.
Yetmar ZA; Razi S; Nayfeh T; Gerberi DJ; Mahmood M; Abu Saleh OM
Int J Antimicrob Agents; 2022 Jan; 59(1):106486. PubMed ID: 34839007
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
Huang V; Rybak MJ
J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.
Bos JC; Prins JM; Mistício MC; Nunguiane G; Lang CN; Beirão JC; Mathôt RAA; van Hest RM
J Antimicrob Chemother; 2018 Jun; 73(6):1620-1629. PubMed ID: 29522167
[TBL] [Abstract][Full Text] [Related]
19. Inoculum effect of high concentrations of methicillin-susceptible Staphylococcus aureus on the efficacy of cefazolin and other beta-lactams.
Saeki M; Shinagawa M; Yakuwa Y; Nirasawa S; Sato Y; Yanagihara N; Takahashi S
J Infect Chemother; 2018 Mar; 24(3):212-215. PubMed ID: 29198902
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus.
Soon RL; Turner SJ; Forrest A; Tsuji BT; Brown J
Int J Antimicrob Agents; 2013 Jul; 42(1):53-8. PubMed ID: 23684388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
